KOD vs PBYI
KOD: Kodiak Sciences is a clinical-stage biotech company developing next-generation, high-durability retinal medicines using its proprietary Antibody Biopolymer Conjugate (ABC) platform. PBYI: Puma Biotechnology is an oncology-focused biopharmaceutical company commercializing the breast cancer drug NERLYNX and developing a pipeline of targeted therapies including the Aurora Kinase A inhibitor alisertib.
Side-by-side fundamentals
| Metric | KOD | PBYI | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $94.26 | $9.97 | |
| Market cap | $5.9B | $515M | |
| P/E as of 2026-10-08 | n/a | 20.90 | |
| Net margin FY2025, SEC XBRL | n/a | +13.6% | |
| Operating margin FY2025, SEC XBRL | n/a | +16.3% | |
| ROE FY2025, SEC XBRL | -146.1% | +23.9% | PBYI higher |
| ROA FY2025, SEC XBRL | -65.4% | +14.4% | PBYI higher |
| Debt / equity as of 2026-09-02 | 0.00 | 0.09 | KOD lower |
| Revenue growth (YoY) as of 2026-09-02 | n/a | -2.4% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +0.0% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.86 | 0.71 | |
| 1-year return as of 2026-10-08 close | +551.9% | +90.6% | KOD higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.